Results of The CAREgiver Burden in BBS (CARE-BBS) study show multifaceted burden of hyperphagiaBOSTON, July 19, 2023 (GLOBE NEWSWIRE) --…
VANCOUVER, British Columbia, July 19, 2023 (GLOBE NEWSWIRE) -- Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore Health” or the “Company”)…
Patients meeting the selection criteria are currently being pre-screened for entry into the Phase 2 Depression trialEthics and clinical trials…
PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / July 19, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis"…
STONY BROOK, NY / ACCESSWIRE / July 18, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA"), a leader in…
Phase 2 Trials in Relapsed/Refractory and Frontline Settings Planned, APVO436 to be administered in Combination with Emerging Standard of CareNew…
FT. MYERS, FL / ACCESSWIRE / July 18, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and…
Celularity will present benchtop and clinical case studies suggesting the therapeutic potential of its human placental-derived biomaterials at ICBST23, the…
ANAHEIM, CA, July 18, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and…
Developing Prosprune® Recognizing the need for an alternative to the endangered Pygeum africanum, the research team at Cepham analyzed various…